The importance of long-term tolerability in achieving recovery

References

• Hirschfeld RM, Schatzberg AF. Long-term management of depression. Am J Med 1994; 97(Suppl 6A): 33S–8S
   Google Scholar
• Hirschfeld RM. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996; 11: 211–7
   Google Scholar
• Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998; 44: 348–60
   PubMed Web of Science ®Google Scholar
• NIMH/NIH. Consensus Development Conference statement. Mood disorders: Pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry 1985; 142: 469–76
   Google Scholar
• Keller MB. Long-term treatment of recurrent and chronic depression. J Clin Psychiatry 2001; 62(Suppl 24)3–5
   PubMed Web of Science ®Google Scholar
• Keller MB. Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 2002; 17(Suppl 1)S43–6
   PubMedGoogle Scholar
• Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30: 165–9
   Google Scholar
• Dalery J, Dagens-Lafont V, De Bodinat C. Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression. Hum Psychopharmacol 2001; 16: S39–47
   Google Scholar
• Franchini L, Spagnolo C, Rampoldi R, et al. Long-term treatment with citalopram in patients with highly recurrent forms of unipolar depression. Psychiatry Res 2001; 105: 129–33
   Google Scholar
• Franchini L, Gasperini M, Perez J, et al. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 1997; 58: 104–7
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11: 137–45
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Perel JM. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 63–73
   PubMed Web of Science ®Google Scholar
• Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096–104
   PubMed Web of Science ®Google Scholar
• Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22–7
   PubMedGoogle Scholar
• Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993; 34: 146–51
   PubMed Web of Science ®Google Scholar
• Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7(Suppl 1)11–17
   PubMedGoogle Scholar
• Wade, AG. Sleep problems in depression – How do they impact treatment and recovery?. Int J Psychiatry Clin Pract 2006;10((Suppl 1)):38–44.
   Google Scholar
• Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry 1997; 58(Suppl 7)5–10
   PubMed Web of Science ®Google Scholar
• Wade, A. A holistic evaluation of attitudes to depression. Poster presented at 16th Annual Scientific Meeting of DURG (in association with the British Society for Pharmacoepidemiology). 27 January, 2005, London, UK.
   Google Scholar
• Braestrup C, Sanchez C. Escitalopram: A unique mechanism of action. Int J Psychiatry Clin Pract 2004; 8(Suppl 1)11–13
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6
   PubMed Web of Science ®Google Scholar
• Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–7
   PubMed Web of Science ®Google Scholar
• Ninan, PT (USA) , Ventura, D, Wang, J. Escitalopram is effective and well tolerated in the treatment of severe depression. Presented at the 156th Annual Meeting of the American Psychiatric Association (APA), 17–22 May, 2003, San Francisco, , CA, .
   Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57–64
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Venture D, Chang C-C, Korotzer A. Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2003; 13(Suppl 4)S263
   Google Scholar
• Alexopoulos, GS (Australia) , Privitera, W, Ventura, D, et al. Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50–200 mg/day) in a randomised, double blind comparison in depressed patients. Poster presented at the International Congress of Biological Psychiatry (ICBP), 9–11 February, 2004, Sydney, .
   Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40–4
   PubMed Web of Science ®Google Scholar
• Auquier P, Robtail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract 2003; 7: 259–68
   PubMed Web of Science ®Google Scholar
• Kasper S. Unique mechanism of action for escitalopram: does it hold the promise?. Int J Psychiatry Clin Pract 2004; 8(Suppl 1)15–18
   PubMedGoogle Scholar
• Wade, A. (Canada) Long-term treatment of depression with escitalopram is safe and well-tolerated. Poster presented at the Collegium Internationale Neuro-Psychopharmacologicum (CINP), 23–27 June, 2002, Montreal, .
   Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44–9
   PubMed Web of Science ®Google Scholar
• Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Curr Med Res Opin 2005; 21: 1659–68
   PubMed Web of Science ®Google Scholar
• Wade, A (Monaco) , Despiegel, N, Reines, E. Escitalopram provides continued improvement during long term treatment of depressed patients in primary care. Poster presented at the 3rd International Forum on Mood and Anxiety Disorders, 27–30 November, 2002, Monte Carlo, .
   Google Scholar
• Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37(Suppl 1)S39–45
   PubMedGoogle Scholar
• Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004; 3: 457–70
   PubMedGoogle Scholar
• Baldwin, DS, Cooper, J, Huusom, AKT. Sexual dysfunction in major depression and during double-blind treatment with escitalopram or paroxetine. Poster presented at the Summer Meeting of the British Association for Psychopharmacology, 25–28 July, 2004, Harrogate, UK.
   Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65–9
   PubMedGoogle Scholar
• Fava M, Mulroy R, Alpert J. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154: 1760–2
   PubMed Web of Science ®Google Scholar
• Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24: 183–97
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44: 77–87
   PubMed Web of Science ®Google Scholar
• Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: Comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17: 217–25
   PubMed Web of Science ®Google Scholar
• Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000; 176: 363–8
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: Effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15: 305–18
   PubMed Web of Science ®Google Scholar
• Baldwin, DS, Montgomery, SA, Nil, R, Lader, M. Discontinuation symptoms in depression and anxiety disorders. Presented at the World Congress of Biological Psychiatry, 28 June–1 July, 2005, Austria.
   Google Scholar
• Baldwin DS, Hindmarch I, Huusom AKT, Cooper J. Escitalopram and paroxetine in the short- and long-term treatment of major depressive disorder (MDD). Int J Neuropsychopharmacol 2004; 7(Suppl 2)S168–9
   Google Scholar
• Murphy GM, Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830–5
   PubMed Web of Science ®Google Scholar